LFVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Lifevantage Corp
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 27, 2026
$5.98−0.02 (-0.33%)
Close on Oct 19, 2026
- Market cap
- $74.97M
- P/E (TTM)
- 15.0
- Dividend yield
- 3.09%
Lifevantage Corp revenue by segment
By business segment
By product or service
| Revenue | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Protandim product line | $19.05M | $19.95M | $20.93M | $22.06M | $23.09M | $23.50M | $24.54M | $24.20M | – | – | – | – | 45.0% | -17.5% |
| LifeVantage product line | $9.61M | $6.32M | $7.22M | – | $17.42M | $16.27M | $23.74M | – | – | – | – | – | 22.7% | -44.8% |
| TrueScience product line | $9.01M | $8.89M | $10.08M | $9.11M | $11.26M | $11.70M | $12.97M | $3.90M | – | – | – | – | 21.3% | -20.0% |
| AXIO product line | $4.20M | $3.43M | $3.92M | $3.46M | $4.35M | $3.89M | $3.54M | $3.53M | – | – | – | – | 9.9% | -3.5% |
| LoveBiome Product Line | $2.87M | $3.18M | $4.07M | – | $0 | $0 | $0 | – | – | – | – | – | 6.8% | – |
| PhysIQ product line | $667.00K | $847.00K | $1.05M | $1.24M | $1.32M | $1.37M | $1.27M | $1.14M | – | – | – | – | 1.6% | -49.4% |
| Petandim product line | $516.00K | $466.00K | $501.00K | $477.00K | $523.00K | $553.00K | $508.00K | $534.00K | – | – | – | – | 1.2% | -1.3% |
| Other | $251.00K | $632.00K | $1.16M | $1.36M | $2.25M | $1.17M | $1.20M | $1.11M | – | – | – | – | 0.6% | -88.9% |
| LifeVantage TrueScience Skin Care Regimen | – | – | – | $9.87M | – | – | – | $12.79M | – | – | – | – | – | – |
By region
| Revenue | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $30.98M | $32.47M | $36.74M | $35.22M | $41.36M | $46.43M | $55.38M | $35.27M | $36.23M | $35.33M | $37.22M | $36.90M | 73.1% | -25.1% |
| Non-US | $11.40M | $11.24M | $12.19M | $12.35M | $13.75M | $12.01M | $12.38M | $11.95M | – | – | – | – | 26.9% | -17.1% |
| Japan | $6.06M | $5.61M | $6.28M | $6.19M | $6.90M | $6.24M | $6.28M | $5.98M | $5.94M | $6.22M | $7.31M | $7.52M | 14.3% | -12.1% |
| Other foreign markets | $5.34M | $5.63M | $5.92M | $6.15M | $6.86M | $5.77M | $6.10M | $5.96M | – | – | – | – | 12.6% | -22.2% |
| Americas | – | – | – | – | – | $48.20M | $57.15M | $36.89M | $38.11M | $37.22M | $39.07M | $38.51M | – | – |
| Asia/Pacific & Europe | – | – | – | – | – | $10.24M | $10.61M | $10.32M | $10.82M | $11.03M | $12.56M | $12.85M | – | – |
From the segment and revenue-disaggregation notes of Lifevantage's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.